Herceptin
FDA unanimously recommends Mylan and Biocon’s Herceptin biosimilar
July 14, 2017Manufacturing and Production, Medical Communications, Sales and Marketing Biocon, Herceptin, Mylan, biosimilar, biotech, drugs, healthcare, life sciences, pharma, pharmaceuticals
Mylan and Biocon have revealed that their biosimilar version of Roche and Genentech’s Herceptin (trastuzumab) has received unanimous recommendation from …
Mylan’s pathway to launch of biosimilar to Herceptin cleared by Roche
March 13, 2017Manufacturing and Production, Sales and Marketing Genentech, Herceptin, Mylan, Roche, biosimilar
Mylan scored a big victory in its plan to launch its biosimilar to Roche’s blockbuster, Herceptin, after Roche and itself …
Roche’s neoadjuvant breast cancer combo therapy shows strong Phase 3 results
March 2, 2017Research and Development Herceptin, Perjeta, Roche
Roche’s combination treatment of Perjeta (pertuzumab), Herceptin (trasdtuzumab) and chemotherapy met its primary endpoint in a recent Phase 3 study. …
EMA accepts regulatory submission for proposed Herceptin biosimilar
August 26, 2016Medical Communications Biocon, EMA, Herceptin, Mylan, biosimilar, regulatory, submission, trastuzumab
Mylan and Biocon have announced that the European Medicines Agency (EMA) has accepted for review its marketing authorisation application for …
Phase III study confirms similarity of Herceptin biosimilar from Amgen, Allergan
July 22, 2016Medical Communications, Research and Development Allergan, Amgen, Herceptin, Roche, biosimilar, trastuzumab
Amgen and Allergan have announced the results from a Phase III study investigating ABP 980, their biosimilar candidate for Roche’s …
Mylan’s breast cancer biosimilar matches Roche’s Herceptin in Phase III trial
June 6, 2016Research and Development ASCO, Biocon, Herceptin, Mylan, Roche, biosimilar, breast cancer, trastuzumab
Mylan (NASDAQ: MYL) and Biocon (NSE: BIOCON) have presented data the 2016 American Society of Clinical Oncology (ASCO) annual meeting …
Two-drug combo shown to significantly shrink breast cancer in days
March 10, 2016Medical Communications, Research and Development GSK, Herceptin, Novartis, Roche, Tyverb
Results of a clinical trial have revealed that Novartis’ Tyverb (lapatinib), in combination with Roche’s Herceptin (trastuzumab), can significantly shrink …
Roche beats estimates with strong 2015 sales
January 28, 2016Medical Communications, Sales and Marketing Esbriet, Herceptin, Roche, avastin
Roche reported full-year financial results today, beating analysts’ estimates, with the Swiss drugmaker announcing Group sales increases for 2015 in …
Breast cancer treatment market booming
March 19, 2015Research and Development, Sales and Marketing Frost, Herceptin, Kadcyla, Roche, breast cancer, oncology, targeted, tykerb
The increased use of combined targeted therapies for breast cancer is set to lift the market and improve progression-free disease …
Herceptin faces UK competition within months
April 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biocon, Herceptin, Hospira, Perjeta, breast cancer
Roche’s blockbuster breast cancer drug Herceptin may soon be under threat from copycat treatments after a court in the UK …
Novartis sues Biocon
April 4, 2014Sales and Marketing Biocon, Galvus, Gilead, Herceptin, Novartis, sofosbuvir
India’s status as a battleground for patent issues has been reinforced with the news that Novartis is suing Biocon over …
India court grants Herceptin injunction
February 10, 2014Research and Development, Sales and Marketing Biocon, Herceptin, India, Mylan, Roche
Roche has been granted an injunction by a court in India to prevent generic manufacturers of its ageing breast cancer …
Herceptin biosimilar set for Indian market
January 21, 2014Research and Development, Sales and Marketing Biocon, Herceptin, Roche, biosimilars, canmab
Biocon has said its generic version of Roche’s ageing breast cancer drug Herceptin will go on sale in India from …
The new paradigm in oncology drug marketing
October 21, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Herceptin, Roche, marketing, oncology
Twenty years ago drugs to treat cancer were made up of chemotherapy agents which are essentially ‘blunt tools’ against the …
Roche rules out merger talk
October 18, 2013Sales and Marketing Cancer, Herceptin, Novartis, Roche, merger
Roche has dismissed talk of merging with fellow Swiss manufacturer Novartis as it revealed its results for the last three …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
